Observation of Alectinib‐ and Crizotinib‐ included chemotherapy in children with ALK‐positive anaplastic large cell lymphoma: A single institutional experience
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5479
Abstract: Approximately one‐third children with anaplastic large cell lymphoma (ALCL) relapse after completion of chemotherapy, particularly for those high‐risk patients. The introduction of novel therapeutic modalities is much needed for these sub‐group patients. Two groups (n… read more here.
Keywords: cell lymphoma; large cell; alectinib; anaplastic large ... See more keywords
Alectinib: A Review in Advanced, ALK-Positive NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0952-0
Abstract: Alectinib (Alecensa®) is a potent and highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Oral alectinib monotherapy is approved in the EU as first-line treatment for adults with advanced ALK-positive non-small cell lung cancer… read more here.
Keywords: positive nsclc; nsclc; advanced alk; treatment ... See more keywords
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2018 at "PharmacoEconomics"
DOI: 10.1007/s40273-018-0625-6
Abstract: BackgroundThe recently completed ALEX trial demonstrated that alectinib improved progression-free survival, and delayed time to central nervous system progression compared with crizotinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. However, the long-term clinical… read more here.
Keywords: alectinib crizotinib; anaplastic lymphoma; cost; alectinib ... See more keywords
The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer letters"
DOI: 10.1016/j.canlet.2017.04.022
Abstract: Activating germline mutations of anaplastic lymphoma kinase (ALK) occur in most cases of hereditary neuroblastoma (NB) and the constitutively active kinase activity of ALK promotes cell proliferation and survival in NB. Therefore, ALK kinase is… read more here.
Keywords: alk; apoptosis; neuroblastoma; alectinib ... See more keywords
Sequential Therapy with Crizotinib and Alectinib in ALK‐Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective Study
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.07.022
Abstract: Introduction: Alectinib and crizotinib have been approved for the therapy of NSCLC caused by anaplastic lymphoma kinase gene (ALK) rearrangement. The effect of alectinib or crizotinib on overall survival (OS) in patients with ALK‐rearranged NSCLC… read more here.
Keywords: alectinib crizotinib; crizotinib; treated group; crizotinib alectinib ... See more keywords
Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
Sign Up to like & getrecommendations! Published in 2023 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001507
Abstract: In view of the success of targeted therapy in the field of advanced lung cancer, it is gradually pushed further to neoadjuvant therapy. Alectinib has been recommended for advanced anaplastic lymphoma kinase (ALK) + non-small cell lung… read more here.
Keywords: locally advanced; lung adenocarcinoma; advanced lung; neoadjuvant alectinib ... See more keywords
Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13983
Abstract: Anaplastic lymphoma kinase (ALK) rearrangements are drivers of a subset of non‐small cell lung cancer (NSCLC). The rapid progression of ALK inhibitors has significantly prolonged the progression‐free survival of patients with ALK gene‐sensitive mutations. However,… read more here.
Keywords: lung cancer; cell lung; non small; cancer ... See more keywords
ALK ‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14347
Abstract: To the Editor, A 71-year-old nonsmoking female was admitted to our hospital with a persistent left gingival mass which had been increasing in size for 2 weeks. The mass had dramatically increased in size, approximately… read more here.
Keywords: alectinib; figure; lung; alk ... See more keywords
Acanthocytosis in an alectinib‐treated patient
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18020
Abstract: An 85- year- old woman who was being treated for an ALK-positive bronchial adenocarcinoma with alectinib, an ALK (anaplastic lymphoma kinase) inhibitor, was hospitalised with a pulmonary embolus. She was found to have a haemoglobin… read more here.
Keywords: alectinib treated; alectinib; treated patient; acanthocytosis alectinib ... See more keywords
Relative Bioavailability and Food Effect Study of an Oral Suspension of Alectinib in Healthy Volunteers Using Venipuncture and Capillary Microsampling.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and translational science"
DOI: 10.1111/cts.13515
Abstract: Alectinib, approved as 150 mg capsules for the treatment of adults with advanced ALK-positive non-small-cell lung cancer, is being assessed in children with ALK-positive solid and central nervous system tumors. An ad hoc pediatric-friendly suspension… read more here.
Keywords: relative bioavailability; suspension alectinib; capsule; suspension ... See more keywords
Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-19-0649
Abstract: Alectinib is used as a first-line treatment for anaplastic lymphoma kinase (ALK)-rearranged non–small cell lung cancer (NSCLC). Whereas other ALK inhibitors have been reported to be involved in resistance to ATP-binding cassette (ABC) transporters, no… read more here.
Keywords: lung cancer; alk rearranged; alectinib; resistance ... See more keywords